ResMed (NYSE:RMD) PT Raised to $236.00
ResMed (NYSE:RMD – Get Free Report) had its target price lifted by equities research analysts at Needham & Company LLC from $224.00 to $236.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Needham & Company LLC’s price objective would […]